{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:03:02Z","timestamp":1778702582980,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vaccine.2021.04.042","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T00:28:52Z","timestamp":1619224132000},"page":"2506-2513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia"],"prefix":"10.1016","volume":"40","author":[{"given":"C. Raina","family":"MacIntyre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Trent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.042_b0005","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https:\/\/covid19.who.int\/. (Accessed: 2nd December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0010","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1473-3099(20)30512-0","article-title":"Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices","volume":"20","author":"MacIntyre","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0015","doi-asserted-by":"crossref","unstructured":"Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science (80-.). 2020;368:860\u20138.","DOI":"10.1126\/science.abb5793"},{"key":"10.1016\/j.vaccine.2021.04.042_b0020","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(20)30457-6","article-title":"Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study","volume":"20","author":"Kucharski","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0025","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1111\/1462-2920.15225","article-title":"Efforts towards a <scp>COVID<\/scp> -19 vaccine","volume":"22","author":"Br\u00fcssow","year":"2020","journal-title":"Environ Microbiol"},{"key":"10.1016\/j.vaccine.2021.04.042_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Florian","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.04.042_b0035","unstructured":"Draft landscape of COVID-19 candidate vaccines. Available at: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. (Accessed: 2nd December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0040","article-title":"What Pfizer\u2019s landmark COVID vaccine results mean for the pandemic","author":"Evan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.04.042_b0045","article-title":"COVID vaccine excitement builds as Moderna reports third positive result","author":"Evan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.04.042_b0050","unstructured":"Voysey M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England) 0, (2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0055","article-title":"Development of unique Australian COVID-19 vaccine halted","author":"Normile","year":"2020","journal-title":"Science 80-"},{"key":"10.1016\/j.vaccine.2021.04.042_b0060","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"NEJMoa2034577","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.04.042_b0065","unstructured":"WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply. Available at: https:\/\/www.who.int\/publications\/m\/item\/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply. (Accessed: 2nd December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0070","article-title":"Covid-19: How to prioritize worse-off populations in allocating safe and effective vaccines","volume":"371","author":"Schmidt","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.04.042_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jlb\/lsaa050","article-title":"COVID-19 vaccine: vaccinate the young to protect the old?","volume":"7","author":"Giubilini","year":"2020","journal-title":"J Law Biosci"},{"key":"10.1016\/j.vaccine.2021.04.042_b0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0196-6553(82)90003-7","article-title":"The global eradication of smallpox","volume":"10","author":"Strassburg","year":"1982","journal-title":"AJIC Am J Infect Control"},{"key":"10.1016\/j.vaccine.2021.04.042_b0085","doi-asserted-by":"crossref","unstructured":"MacIntyre CR, Costantino V, Mohanty B, Nand D, Kunasekaran MP, Heslop D. Epidemic size, duration and vaccine stockpiling following a large-scale attack with smallpox. Global Biosecurity. 2019;1(1):74\u201381. http:\/\/doi.org\/10.31646\/gbio.13.","DOI":"10.31646\/gbio.13"},{"key":"10.1016\/j.vaccine.2021.04.042_b0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3201\/eid2201.151410","article-title":"Effectiveness of ring vaccination as control strategy for Ebola virus disease","volume":"22","author":"Kucharski","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0095","article-title":"Harnessing Case Isolation and Ring Vaccination to Control Ebola","volume":"9","author":"Wells","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/epirev\/mxz014","article-title":"Postexposure Effects of Vaccines on Infectious Diseases","volume":"41","author":"Gallagher","year":"2019","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2021.04.042_b0105","article-title":"Incubation Period of Severe Acute Respiratory Syndrome Novel Coronavirus 2 that Causes Coronavirus Disease 2019: A Systematic Review and Meta-Analysis","volume":"93","author":"Wassie","year":"2020","journal-title":"Curr Therapeut Res - Clin Exper"},{"key":"10.1016\/j.vaccine.2021.04.042_b0110","unstructured":"COVID-19 vaccination prioritisation | Australian Government Department of Health. Available at: https:\/\/www.health.gov.au\/news\/health-alerts\/novel-coronavirus-2019-ncov-health-alert\/vaccines-and-treatments\/covid-19-vaccination-prioritisation. (Accessed: 2nd December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa081","article-title":"The effectiveness of full and partial travel bans against COVID-19 spread in Australia for travellers from China during and after the epidemic peak in China","volume":"27","author":"Costantino","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2021.04.042_b0120","unstructured":"ABS. National, state and territory population, March 2020 | Australian Bureau of Statistics. (2020). Available at: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release. (Accessed: 15th October 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0125","series-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia","author":"Li","year":"2020"},{"key":"10.1016\/j.vaccine.2021.04.042_b0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.04.042_b0135","doi-asserted-by":"crossref","unstructured":"Bai Lingsheng, Wei Tao, Tian Fei, Jin Dong-Yan, Chen Lijuan, Wang Meiyun YY. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA Published; 2020.","DOI":"10.1001\/jama.2020.2565"},{"key":"10.1016\/j.vaccine.2021.04.042_b0140","unstructured":"COVID-19 Pandemic Planning Scenarios | CDC. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/planning-scenarios.html. (Accessed: 29th June 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijid.2020.04.034","article-title":"The relative transmissibility of asymptomatic COVID-19 infections among close contacts","volume":"94","author":"He","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005697","article-title":"Projecting social contact matrices in 152 countries using contact surveys and demographic data","volume":"13","author":"Prem","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.vaccine.2021.04.042_b0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijid.2020.02.033","article-title":"Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis","volume":"93","author":"Zhang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0160","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.04.042_b0165","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.04.042_b0170","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"NEJMoa2101765","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.04.042_b0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.04.042_b0180","doi-asserted-by":"crossref","unstructured":"Lin Y, Xie B, et al. C. D. Asymptomatic Novel Coronavirus Pneumonia Patient Outside Wuhan: The Value of CT Images in the Course of the Disease. Clin Imaging 2020;63:7\u20139.","DOI":"10.1016\/j.clinimag.2020.02.008"},{"key":"10.1016\/j.vaccine.2021.04.042_b0185","doi-asserted-by":"crossref","unstructured":"Rothe M, Sothmann P, et al. C. S. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020. http:\/\/doi.org\/10.1056\/NEJMc2001468.","DOI":"10.1056\/NEJMc2001468"},{"key":"10.1016\/j.vaccine.2021.04.042_b0190","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients","author":"Zou","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.04.042_b0195","doi-asserted-by":"crossref","DOI":"10.3201\/eid2606.200357","article-title":"Serial Interval of COVID-19 among Publicly Reported Confirmed Cases","volume":"26","author":"Du","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0200","first-page":"264","article-title":"Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020","volume":"5","author":"Mizumoto","year":"2020","journal-title":"Infect Dis Model"},{"key":"10.1016\/j.vaccine.2021.04.042_b0205","unstructured":"Estimating the asymptomatic ratio of 2019\u2026 | Oxford Martin School. Available at: https:\/\/www.oxfordmartin.ox.ac.uk\/publications\/estimating-the-asymptomatic-ratio-of-2019-novel-coronavirus-onboard-the-princess-cruises-ship\/. (Accessed: 24th March 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0210","doi-asserted-by":"crossref","unstructured":"MacIntyre Valentina, Kunasekaram, Mohana Priya, CRC. Health system capacity in Sydney, Australia in the event of a biological attack with smallpox. PLoS One 2019;14.","DOI":"10.1371\/journal.pone.0217704"},{"key":"10.1016\/j.vaccine.2021.04.042_b0215","doi-asserted-by":"crossref","unstructured":"Team, T. N. C. P. E. R. E. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) \u2014 China, 2020. China CDC Wkly. 2020;2:113\u201322.","DOI":"10.46234\/ccdcw2020.032"},{"key":"10.1016\/j.vaccine.2021.04.042_b0220","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 \u2014 COVID-NET, 14 States, March 1\u201330, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.04.042_b0225","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.04.042_b0230","unstructured":"Mass Vaccination Clinics during an Influenza Pandemic Policy manual, Infectious Diseases Population Health-Communicable Diseases. (2018)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0235","unstructured":"Health Workforce Data | Summary Statistics. Available at: https:\/\/hwd.health.gov.au\/summary.html#part-3. (Accessed: 15th October 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0240","article-title":"Estimating the Burden of COVID-19 on the Australian Healthcare Workers and Health System","volume":"103811","author":"Quigley","year":"2020","journal-title":"Int J Nurs Stud"},{"key":"10.1016\/j.vaccine.2021.04.042_b0245","article-title":"Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions","volume":"372","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.04.042_b0250","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1473-3099(20)30633-2","article-title":"Elimination of COVID-19: what would it look like and is it possible?","volume":"20","author":"Heywood","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.04.042_b0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5694\/mja2.50786","article-title":"The probability of the 6-week lockdown in Victoria (commencing 9 July 2020) achieving elimination of community transmission of SARS-CoV-2","volume":"213","author":"Blakely","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2021.04.042_b0260","first-page":"10","article-title":"Cruise Ship Travel and the Spread of COVID-19 \u2013 Australia as a Case Study","volume":"9","author":"Quigley","year":"2021","journal-title":"Int Travel Med Cent Iran"},{"key":"10.1016\/j.vaccine.2021.04.042_b0265","unstructured":"Department of Health and Human Services Victoria | Victorian healthcare worker (clinical and non-clinical) coronavirus (COVID-19) data. Available at: https:\/\/www.dhhs.vic.gov.au\/victorian-healthcare-worker-covid-19-data. (Accessed: 16th December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0270","article-title":"Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.04.042_b0275","doi-asserted-by":"crossref","unstructured":"Foy BH. et al. Comparing COVID-19 vaccine allocation strategies in India: a mathematical modelling study. medRxiv 2020.11.22.20236091, 2020. http:\/\/doi.org\/10.1101\/2020.11.22.20236091.","DOI":"10.1101\/2020.11.22.20236091"},{"key":"10.1016\/j.vaccine.2021.04.042_b0280","unstructured":"Parliament of Victoria - Inquiry into the Victorian Government\u2019s COVID\u201019 Contact Tracing System and Testing Regime. Available at: https:\/\/www.parliament.vic.gov.au\/1005-lsic-lc\/inquiry-into-the-victorian-government-s-covid-19-contact-tracing-system-and-testing-regime. (Accessed: 16th December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0285","unstructured":"We modelled how a COVID vaccine roll-out would work. Here\u2019s what we found. Available at: https:\/\/theconversation.com\/we-modelled-how-a-covid-vaccine-roll-out-would-work-heres-what-we-found-150544. (Accessed: 2nd December 2020)."},{"key":"10.1016\/j.vaccine.2021.04.042_b0290","unstructured":"Aihw. 5.2 Rural and remote populations."},{"key":"10.1016\/j.vaccine.2021.04.042_b0295","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1016\/j.vaccine.2019.07.066","article-title":"Parental opinions towards the \u201cNo Jab, No Pay\u201d policy in Australia","volume":"37","author":"Trent","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.042_b0300","series-title":"Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: a comparative survey in the United States, United Kingdom","author":"Mallory","year":"2020"},{"key":"10.1016\/j.vaccine.2021.04.042_b0305","doi-asserted-by":"crossref","unstructured":"Yamin D, Gerlic M. The rise of SARS-CoV-2 variant B.1.1.7 in Israel intensifies the role of surveillance and vaccination in elderly. medRxiv 2021.02.16.21251819 (2021). http:\/\/doi.org\/10.1101\/2021.02.16.21251819.","DOI":"10.1101\/2021.02.16.21251819"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21005016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:07Z","timestamp":1759403407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21005016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":61,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0264410X21005016"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.042","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.15.20248278","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}